Serum irisin concentrations were increased after transient continuous subcutaneous insulin infusion in type 2 diabetes mellitus patients

- Irisin levels were significantly elevated after CSII treatment in T2DM patients.
- Elevated irisin was accompanied by improved glycemic control and lipid profiles.
- Elevated irisin may represent benefits of ameliorative metabolism following CSII.

Irisin, identified as a novel myokine, plays an important role in improving metabolic disorders, including type 2 diabetes mellitus (T2DM). In this interventional study, we investigated the alteration of serum irisin levels in T2DM subjects after transient continuous subcutaneous insulin infusion (CSII) treatment.